<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04635488</url>
  </required_header>
  <id_info>
    <org_study_id>LLNM-2020</org_study_id>
    <nct_id>NCT04635488</nct_id>
  </id_info>
  <brief_title>Prediction Model for Lateral Lymph Node Metastasis</brief_title>
  <official_title>Radiomics-based Prediction Model for Lateral Lymph Node Metastasis in Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mid to low-lying rectal cancer patient with enlarged lateral lymph node befor treatment and&#xD;
      receiving lateral lymph node dissection would be enrolled. Radiomics parameters of lateral&#xD;
      lymph nodes would be extracted by expert software. Then a part of the nodes would be used as&#xD;
      the training set to build the prediction model, and the another part nodes would be used as&#xD;
      the validation set.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After performing lateral lymph node dissection for the enrolled patients, we would find the&#xD;
      targeted lateral node which was matched with the enlarged one in imaging from the specimen.&#xD;
      Then the nodes would be send for pathological examination. Then we would extract the&#xD;
      radiomics parameters of the nodes from the pretreatment CT and MRI with ITK-SNAP software.&#xD;
      According to the pathological status, lymph nodes and corresponding radiomics parameters&#xD;
      would be divided into positive and negative groups. Then significant parameters would be&#xD;
      selected by R software. Then the prediction model with nomogram would be developed. 70% nodes&#xD;
      would be used for for model development and the other 30% would be used for validation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>metastasis rate of lateral lymph node</measure>
    <time_frame>2020.1-2022.12.31</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Trainning group</arm_group_label>
    <description>70% of the whole participants would be randomly divided into the training group to build the predicition model.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>validation group</arm_group_label>
    <description>30% of the whole participant would be divided into the validation group to validate the model</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lateral lymph node dissection</intervention_name>
    <description>All participted would receive lateral lymph node dissection for rectal cancer.</description>
    <arm_group_label>Trainning group</arm_group_label>
    <arm_group_label>validation group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with rectal cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  middle to low-lying rectal adenocarcinoma patients with enlarged lateral lymph node&#xD;
             â‰¥5mm for short diameter in CT and/or MRI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other kind of rectal tumor including neuroendocrine and malignant.&#xD;
&#xD;
          -  high location rectal cancer.&#xD;
&#xD;
          -  recurrent rectal cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ziqiang Wang, MD</last_name>
    <phone>18980602028</phone>
    <email>wangziqiang@scu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xubing Zhang, MD</last_name>
    <phone>18428374478</phone>
    <email>2421770462@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guoxue Road 37#,West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziqiang Wang, MD</last_name>
      <phone>18980602028</phone>
      <email>wangziqiang@scu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Ziqiang Wang,MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>lymph node metastasis</keyword>
  <keyword>prediction model</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>individual participant data (IPD) would not be available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

